Emiko Azuma - Takeda Pharmaceutical Independent Director
| TAK Stock | USD 13.03 0.04 0.31% |
Director
Ms. Emiko Azuma was serving as Independent Director in Takeda Pharmaceutical Company Limited since June 2016. She is also serving as Independent Director in MetLife Insurance, K.K., KLATencor Corporation and InvenSense Corporationrationration, as well as Managing Director in Tomon Partners, LLC. since 2016.
| Age | 59 |
| Tenure | 8 years |
| Address | 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has Return on Asset of 0.0261 % which means that on every $100 spent on assets, it made $0.0261 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0276 %, implying that it generated $0.0276 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Takeda Pharmaceutical's Return On Tangible Assets are quite stable compared to the past year. Return On Equity is expected to rise to 0.1 this year, although the value of Return On Capital Employed will most likely fall to 0.05. At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 16.9 T this year, although the value of Non Current Liabilities Other will most likely fall to about 383.9 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Larry Bird | PetIQ Inc | 63 | |
| Will Santana | PetIQ Inc | 45 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Corinne Nevinny | Neurocrine Biosciences | 57 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Gary Michael | PetIQ Inc | 77 | |
| Susan Sholtis | PetIQ Inc | 51 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Mark First | PetIQ Inc | 53 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| James Clarke | PetIQ Inc | 45 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Joseph Mollica | Neurocrine Biosciences | 59 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Scott Huff | PetIQ Inc | 46 | |
Management Performance
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian Clark, Independent Director | ||
| Gregory Hayes, Interim CFO, Corporate Secretary | ||
| Constantine Saroukos, CFO Director | ||
| Salvatore MD, Member Policy | ||
| Neil Swift, interim President and CEO | ||
| C Wasser, Director | ||
| Milano Furuta, Chief Officer | ||
| Lori Walton, Director | ||
| Masami Iijima, Independent Director | ||
| Christophe Weber, President, Chief Executive Officer, Representative Director | ||
| Masahiro Sakane, Independent Chairman of the Executive Board | ||
| Seigo Izumo, Chair Board | ||
| Olivier Bohuon, Independent Director | ||
| Gabriele Ricci, Chief Officer | ||
| Ken Araki, Vice Department | ||
| JeanLuc Butel, Independent Director | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Senior Department | ||
| Michel Orsinger, Independent Director | ||
| Dennis Fentie, Director | ||
| Peter Bures, Director | ||
| Shiro Kuniya, Independent Director | ||
| Emiko Azuma, Independent Director | ||
| Christopher OReilly, Global Finance | ||
| Toshiyuki Shiga, Independent Director | ||
| Dave Glover, IR Contact Officer | ||
| Steven Gillis, Independent Director | ||
| Mwana Lugogo, Chief Officer | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller | ||
| Masato Iwasaki, President of Japan Pharma Business Unit, Director | ||
| Yasuhiko Yamanaka, Director | ||
| Emiko Higashi, Independent Director | ||
| Janet LeeSheriff, Director | ||
| Patricia Wilson, Independent Director | ||
| Andrew Plump, President of Research & Development, Vice President of Subsidiary, Director | ||
| Costa Saroukos, Chief Financial Officer, Director | ||
| Tokumasa Takeda, IR Contact Officer | ||
| Yoshiaki Fujimori, Independent Director | ||
| Koji Hatsukawa, Independent Director | ||
| Yoshihiro Nakagawa, Global Counsel |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 4.94 T | ||||
| Shares Outstanding | 3.14 B | ||||
| Shares Owned By Institutions | 2.67 % | ||||
| Number Of Shares Shorted | 5.97 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.95 X |
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Takeda Stock analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stocks Directory Find actively traded stocks across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Dividend Share 184 | Earnings Share 0.36 | Revenue Per Share 1.3 K | Quarterly Revenue Growth 0.013 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.